Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 813-823

  Pollock, Brad H ^a   DeBaun, Michael R ^a   Camitta, Bruce M ^a   Shuster, Jonathan J ^a   Ravindranath, Yaddanapudi ^a   Pullen, D Jeanette ^a   Land, Vita J ^a   Mahoney Jr , Donald H ^a   Lauer, Stephen J ^a   Murphy, Sharon B ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0033966455     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.813     Document Type: Article

References (32)

1. Camitta BM, Pullen J, Murphy S: Biology and treatment of acute lymphocytic leukemia in children. Semin Oncol 24:83-91, 1997
2. Pui CH, Boyett JM, Hancock ML, et al: Outcome of treatment for childhood cancer in black as compared with white children: The St Jude Children's Research Hospital experience, 1962 through 1992. JAMA 273:633-637, 1995
3. Novakovic B: U.S. childhood cancer survival, 1973-1987. Med Pediatr Oncol 23:480-486, 1994
4. Sather H, Honour R, Sposto R, et al: Differences in the presentation of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in black children and white children: A report from the Epidemiology Committee of the Children's Cancer Study Group, in Magrath IT, Conor GT, Ramot B (eds): Pathogenesis of Leukemias and Lymphomas: Environmental Influences. New York, NY, Raven Press, 1984, pp 179-189
5. Falletta JM, Boyett J, Pullen DJ, et al: Clinical and phenotypic features of childhood acute lymphocytic leukemia in whites, blacks, and Hispanics: A Pediatric Oncology Group study, in Magrath IT, Conor GT, Ramot B (eds): Pathogenesis of Leukemias and Lymphomas: Environmental Influences. New York, NY, Raven Press, 1984, pp 191-195
6. Kalwinsky DK, Rivera G, Dahl GV, et al: Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukaemia: Implications for treatment outcome. Leuk Res 9:817-823, 1985
7. Walters TR, Bushore M, Simone J: Poor prognosis in Negro children with acute lymphocytic leukemia. Cancer 29:210-214, 1972
8. Hord MH, Smith TL, Culbert SJ, et al: Ethnicity and cure rates of Texas children with acute lymphoid leukemia. Cancer 77:563-569, 1996
9. Borowitz MJ, Carroll AJ, Shuster JJ, et al: Use of clinical and laboratory features to define prognostic subgroups in B-precursor acute lymphoblastic leukemia: Experience of the Pediatric Oncology Group. Recent Results Cancer Res 131:257-267, 1993
10. Smith M, Bleyer A, Crist W, et al: Uniform criteria for childhood acute lymphoblastic leukemia risk classification. J Clin Oncol 14:680-681, 1996 (letter)
11. Look A, Roberson P, Williams D, et al: Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 65:1079-1086, 1985
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: Analysis and examples. Br J Cancer 35:1-39, 1977
14. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
15. Pullen J, Boyett J, Shuster J, et al: Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11:839-849, 1993
16. Land VJ, Shuster JJ, Crist WM, et al: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1939-1945, 1994
17. Camitta B, Mahoney D, Leventhal B, et al: Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1383-1389, 1994
18. Mahoney DH Jr, Camitta BM, Leventhal BG, et al: Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group pilot study. Cancer 75:2623-2631, 1995
19. Pollock BH: Quality assurance for interventions in clinical trials: Multicenter data monitoring, data management, and analysis. Cancer 74:2647-2652, 1994
20. Vietti J, Shuster J, Amylon M, et al: Progress against childhood cancer: The Pediatric Oncology Group experience. Pediatrics 89:597-600, 1992
21. Bhatia S, Sather H, Zhang J, et al: Ethnicity and survival following childhood acute lymphoblastic leukemia (ALL): Follow-up of the Children's Cancer Group (CCG) cohort. Proc Am Soc Clin Oncol 18:568a, 1999 (abstr 2190)
22. Relling MV, Hancock ML, Boyett JM, et al: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817-2823, 1999
23. Viana MB, Murao M, Ramos G, et al: Malnutrition as a prognostic factor in lymphoblastic leukaemia: A multivariate analysis. Arch Dis Child 71:304-310, 1994 (letter)
24. Pinkle D: Acute lymphoid leukemia outcomes in black and white children. JAMA 274:379-380, 1995
25. Pui CH, Hancock ML, Smith KR, et al: Acute lymphoid leukemia outcomes in black and white children. JAMA 274:380, 1995 (letter)
26. Dayal HH, Chiu C: Factors associated with racial differences in survival for prostatic carcinoma. J Chronic Dis 35:553-560, 1982
27. Eley JW, Hill HA, Chen VW, et al: Racial differences in survival from breast cancer: Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 272:947-954, 1994
28. Bach PB, Cramer LD, Warren JL, et al: Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341:1198-1205, 1999
29. Matherly LH, Taub JW, Wong SC, et al: Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood 90:578-589, 1997
30. Schmiegelow K, Schroder H, Gustafsson G, et al: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy: Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13:345-351, 1995
31. Graham ML, Shuster JJ, Kamen BA, et al: Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: A Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol 31:217-222, 1992
32. Graham ML, Shuster JJ, Kamen BA, et al: Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: A Pediatric Oncology Group study. Clin Cancer Res 2:331-337, 1996